GDC-0425 is an orally bioavailable and highly selective small molecule ChK1 inhibitor. It has potential antineoplastic and chemosensitization activities, selectively binding to Chk1 to prevent its activity and abrogate DNA repair. This action leads to the accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis, making it suitable for research into various malignancies.
- Orally available
- Highly selective ChK1 inhibitor
- Potential antineoplastic and chemosensitization activities
- Selectively binds to Chk1, preventing its activity
- Abrogates the repair of damaged DNA
- Leads to accumulation of damaged DNA
- Induces apoptosis
- May enhance the cytotoxicity of DNA-damaging agents
- May reverse tumor cell resistance to chemotherapeutic agents